Exclusive: NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004
People with motor neurone disease have spoken of their devastation over the likely loss of access to a life-extending drug due to an NHS cost threshold that has not been raised since 2004.
Tofersen has slowed the progress of the illness in trials, but the chances of the drug being recommended for use in England and Wales are said to be slim.
